You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
AstraZeneca
Express Scripts
Merck
Johnson and Johnson

Last Updated: March 29, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022201


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 022201 describes FIRMAGON, which is a drug marketed by Ferring and is included in one NDA. There are three patents protecting this drug. Additional details are available on the FIRMAGON profile page.

The generic ingredient in FIRMAGON is degarelix acetate. Additional details are available on the degarelix acetate profile page.
Summary for 022201
Tradename:FIRMAGON
Applicant:Ferring
Ingredient:degarelix acetate
Patents:3
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 022201
Generic Entry Date for 022201*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for 022201
Tradename Dosage Ingredient NDA Submissiondate
FIRMAGON POWDER;SUBCUTANEOUS degarelix acetate 022201 2019-12-20

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;SUBCUTANEOUSStrengthEQ 80MG BASE/VIAL
Approval Date:Dec 24, 2008TE:RLD:Yes
Patent:  Start TrialPatent Expiration:May 18, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
Patent:  Start TrialPatent Expiration:Apr 27, 2032Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING PROSTATE CANCER
Patent:  Start TrialPatent Expiration:Feb 10, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Medtronic
Harvard Business School
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.